Patent litigation attorney
Sharick Naqi
2 tracked appearances — 2 plaintiff · 0 defendant.
Specialty & background
Specialty / focus. Sharick Naqi is a life-sciences patent litigator. His docketed work centers on pharmaceutical and Hatch-Waxman disputes — Orange Book method-of-treatment and formulation patents, ANDA litigation, and IPRs — including the multi-party fight over Novartis's Gilenya (fingolimod 0.5 mg) patent and monoclonal-antibody matters (his 2018 PTAB declaration in Pfizer v. Genentech cited particular experience with antibody therapies). His background is biomedical engineering, and he now handles gene-therapy IP in-house.
Side preference / firm context. Both tracked appearances (2 of 2) were plaintiff-side, with Naqi representing generic manufacturers — Sun Pharmaceutical Industries, Ltd. and Actavis Elizabeth LLC et al. — against Novartis AG while at Winston & Strawn (Chicago), where he rose from summer associate to senior associate in patent litigation; his second tracked role was as counsel of record in Actavis Elizabeth LLC et al. v. Novartis AG. Court filings from his Winston years also list him among counsel for Teva Pharmaceuticals in Acorda Therapeutics v. Alkem Laboratories (D. Del.), so his private-practice work spanned both sides of the docket for operating companies rather than NPE/PAE enforcement. After Winston, he was a senior associate in IP litigation at Kirkland & Ellis and served a corporate-counsel secondment at Hikma Pharmaceuticals; he is now in-house at Novartis — as of the November 2023 Mayer Brown life-sciences symposium, he was Director and Senior Counsel, IP Lead at Novartis Gene Therapies.
Notable cases / outcomes. The tracked matters align with the consolidated challenge to U.S. Patent No. 9,187,405 (method of treating relapsing-remitting MS with 0.5 mg/day fingolimod): joined IPRs IPR2017-00854, -01550, -01929, and -01946, in which the PTAB's July 2018 final written decision upheld claims 1–6, rejecting the generics' obviousness and anticipation grounds; the Actavis-side appeal followed in the Federal Circuit (No. 18-2260, filed August 2018; docket closed March 2019).
PTAB / IPR experience. Yes — he appeared regularly on the petitioner side: the Gilenya IPRs above; as back-up counsel in IPR2017-01357 (withdrawn in August 2018 when he left Winston & Strawn); and in Pfizer v. Genentech, IPR2017-01489, where he sought pro hac vice admission while at Kirkland & Ellis. Bar / education: Illinois bar (per his 2018 PTAB declaration); B.S. Biomedical Engineering, Johns Hopkins University; J.D., Northwestern Pritzker School of Law. He began his career as a USPTO patent examiner.
Firms
Roles
- back-up counsel1
- counsel of record1
Cases (2)
- π plaintiffActavis Elizabeth LLC et al. v. Novartis AGWinston & Strawn · counsel of record
- π plaintiffSun Pharmaceutical Industries, Ltd. v. Novartis AGWinston & Strawn · back-up counsel